Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,214 across all filing types
Latest filing 2025-12-14 Board/Management Inform…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
Board/Management Information Classification · 1% confidence The document is a Form 6-K filing submitted to the SEC. The content explicitly announces the resignation of the current Chief Financial Officer and the appointment of a new Chief Financial Officer. According to the filing definitions, announcements regarding changes in senior management fall under the 'Board/Management Information' (MANG) category.
2025-12-14 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing (under 2,000 characters) from XTL Biopharmaceuticals Ltd. It explicitly states 'Attached hereto is a report on סיום כהונה ומינוי סמנכ
2025-12-14 English
resignation of officers in a subsidiary
Board/Management Information Classification · 1% confidence The document is a Form 6-K filed with the SEC, which is a report of a foreign private issuer. The content specifically announces the resignation of the CEO and CTO of a subsidiary, Social Proxy Ltd. Since the document focuses on changes in senior management personnel, it falls under the 'Board/Management Information' category.
2025-12-14 English
resignation of officers in a subsidiary
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing (under 2,000 characters) from XTL Biopharmaceuticals Ltd. It explicitly states 'Attached hereto is a report on...' followed by a filename, which indicates it is an announcement of a report rather than the report itself. The content concerns the resignation of officers at a subsidiary. According to the 'Menu vs Meal' rule, documents that announce the publication of a report or provide a link/attachment are classified as Report Publication Announcements (RPA). FY 2025
2025-12-14 English
REPORT OF FOREIGN PRIVATE ISSUER
Foreign Filer Report
2025-12-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Foreign Filer Report
2025-12-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.